MX2023001980A - Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo. - Google Patents
Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo.Info
- Publication number
- MX2023001980A MX2023001980A MX2023001980A MX2023001980A MX2023001980A MX 2023001980 A MX2023001980 A MX 2023001980A MX 2023001980 A MX2023001980 A MX 2023001980A MX 2023001980 A MX2023001980 A MX 2023001980A MX 2023001980 A MX2023001980 A MX 2023001980A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- fused imidazole
- method therefor
- imidazole derivative
- medical use
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 150000002460 imidazoles Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen derivados de imidazol fusionados, métodos de preparación para los mismos y usos médicos de los mismos. Específicamente, la presente invención se refiere a un derivado de imidazol fusionado como se muestra en la fórmula general (IM), un método de preparación para el mismo, una composición farmacéutica que contiene el derivado y el uso del mismo como agente terapéutico, en particular el uso del mismo como un agonista del receptor GLP-1, y el uso del mismo en la preparación de fármacos para el tratamiento y/o prevención de la diabetes.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010905693 | 2020-09-01 | ||
CN202010984336 | 2020-09-18 | ||
CN202011124085 | 2020-10-20 | ||
CN202011253077 | 2020-11-11 | ||
CN202011407911 | 2020-12-04 | ||
CN202011627733 | 2020-12-31 | ||
PCT/CN2021/115915 WO2022007979A1 (zh) | 2020-09-01 | 2021-09-01 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001980A true MX2023001980A (es) | 2023-02-27 |
Family
ID=79552285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023001980A MX2023001980A (es) | 2020-09-01 | 2021-09-01 | Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20230322756A1 (es) |
EP (1) | EP4209490A4 (es) |
JP (1) | JP2023539584A (es) |
KR (1) | KR20230058660A (es) |
CN (1) | CN115884969A (es) |
AU (1) | AU2021306414A1 (es) |
CA (1) | CA3188891A1 (es) |
MX (1) | MX2023001980A (es) |
TW (1) | TW202220985A (es) |
WO (1) | WO2022007979A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4192831A4 (en) | 2020-08-06 | 2024-05-15 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環glp-1アゴニスト |
CA3218345A1 (en) | 2021-05-20 | 2022-11-24 | Francisco Javier Agejas Chicharro | Macrocyclic glucagon-like peptide 1 receptor agonists |
CA3227366A1 (en) * | 2021-08-04 | 2023-02-09 | Yidong Su | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
EP4393914A1 (en) * | 2021-08-24 | 2024-07-03 | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. | Imidazocyclic compound and application thereof |
WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
KR20240073108A (ko) | 2021-10-05 | 2024-05-24 | 아스트라제네카 아베 | Glp-1 수용체 조절제로서의 특정 2,5-디아자바이시클로[4.2.0]옥탄 |
WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
WO2023076237A1 (en) | 2021-10-25 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023246833A1 (zh) * | 2022-06-23 | 2023-12-28 | 西藏海思科制药有限公司 | 一种五并五元环衍生物的药物组合物及其在医药上的应用 |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024131869A1 (en) * | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005538953A (ja) | 2002-05-28 | 2005-12-22 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | 新規チオフェンアミジン、それらの組成物、および補体媒介疾患および病気を治療する方法 |
CA2716664C (en) | 2008-03-07 | 2016-10-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds |
CA2757084C (en) | 2009-03-30 | 2017-08-29 | Transtech Pharma, Inc. | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
EP2509975B1 (en) * | 2009-12-04 | 2014-04-23 | Boehringer Ingelheim International GmbH | Benzimidazole inhibitors of leukotriene production |
JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
EP3883928A4 (en) * | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
-
2021
- 2021-09-01 CA CA3188891A patent/CA3188891A1/en active Pending
- 2021-09-01 CN CN202180050847.9A patent/CN115884969A/zh active Pending
- 2021-09-01 WO PCT/CN2021/115915 patent/WO2022007979A1/zh active Application Filing
- 2021-09-01 MX MX2023001980A patent/MX2023001980A/es unknown
- 2021-09-01 EP EP21837580.6A patent/EP4209490A4/en active Pending
- 2021-09-01 AU AU2021306414A patent/AU2021306414A1/en active Pending
- 2021-09-01 KR KR1020237009937A patent/KR20230058660A/ko active Search and Examination
- 2021-09-01 TW TW110132457A patent/TW202220985A/zh unknown
- 2021-09-01 US US18/043,508 patent/US20230322756A1/en active Pending
- 2021-09-01 JP JP2023512797A patent/JP2023539584A/ja active Pending
-
2024
- 2024-03-21 US US18/612,631 patent/US20240246958A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4209490A1 (en) | 2023-07-12 |
US20230322756A1 (en) | 2023-10-12 |
AU2021306414A1 (en) | 2023-05-04 |
CN115884969A (zh) | 2023-03-31 |
WO2022007979A1 (zh) | 2022-01-13 |
KR20230058660A (ko) | 2023-05-03 |
JP2023539584A (ja) | 2023-09-15 |
EP4209490A4 (en) | 2023-11-22 |
CA3188891A1 (en) | 2022-01-13 |
TW202220985A (zh) | 2022-06-01 |
US20240246958A1 (en) | 2024-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001980A (es) | Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo. | |
MX2023006186A (es) | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. | |
MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
CR8047A (es) | Procedimiento de tratamiento de la arterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas | |
UA86977C2 (ru) | Производные гидантоина для лечения обструктивных болезней дыхательных путей | |
AR070842A1 (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 | |
TW200806311A (en) | Neuropeptide-2 receptor-agonists | |
MX2023013890A (es) | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
MX2023011166A (es) | Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. | |
MX2023005533A (es) | Derivado de triazina diona, metodo de preparacion y aplicacion del mismo en medicina. | |
MX2022013054A (es) | Derivados de imidazolidinona y uso medico de los mismos. | |
IL197448A (en) | Long-lasting glp-1 history of a drug used in the preparation of a hyperglycemia and diabetes drug | |
PH12020551939A1 (en) | Pharmaceutical composition comprising sglt-2 inhibitor and dpp-iv inhibitor | |
MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
MX2020013785A (es) | Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo. | |
IN2012DN03042A (es) | ||
MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
MX2023000303A (es) | Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral. | |
MX2009011900A (es) | Curacion de herida diabetica. | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
CN105078909B (zh) | 一种注射用苯磺顺阿曲库铵冷冻干燥组合物及其制备方法 | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
ZA202308118B (en) | Cdk inhibitor | |
WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same |